Peter Reichardt, George D Demetri, Hans Gelderblom, Piotr Rutkowski, Seock-Ah Im, Sudeep Gupta, Yoon-Koo Kang, Patrick Schöffski, Jochen Schuette, Denis Soulières, Jean-Yves Blay, David Goldstein, Kolette Fly, Xin Huang, Massimo Corsaro, Maria Jose Lechuga, Jean-Francois Martini, Michael C Heinrich
BACKGROUND: Several small studies indicated that the genotype of KIT or platelet-derived growth factor receptor-α (PDGFRA) contributes in part to the level of clinical effectiveness of sunitinib in gastrointestinal stromal tumor (GIST) patients. This study aimed to correlate KIT and PDGFRA mutational status with clinical outcome metrics (progression-free survival [PFS], overall survival [OS], objective response rate [ORR]) in a larger international patient population. METHODS: This is a non-interventional, retrospective analysis in patients with imatinib-resistant or intolerant GIST who were treated in a worldwide, open-label treatment-use study (Study 1036; NCT00094029) in which sunitinib was administered at a starting dose of 50 mg/day on a 4-week-on, 2-week-off schedule...
January 15, 2016: BMC Cancer